Abaloparatide

Drug Profile

Abaloparatide

Alternative Names: Abaloparatide TD; Abaloparatide-SC; BA 058; BA-058-SC; BA-058-TD; BIM-44058; ITM-058; PTHrP; Synthetic human parathyroid hormone 37-70 analogue - Ipsen

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator 3M Drug Delivery Systems; Biomeasure Inc; Ipsen
  • Developer Radius; Radius Health Inc.; Teijin Pharma
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Postmenopausal osteoporosis

Highest Development Phases

  • Preregistration Postmenopausal osteoporosis

Most Recent Events

  • 10 Mar 2017 PDUFA action date extended by US FDA to 30/06/2017 for NDA for Postmenopausal osteoporosis
  • 24 Feb 2017 Radius Health has patent protection for abaloparatide in USA, European Union, Canada, Asia, Australia, Russia and New Zealand (Radius Health's form 10-K, filed in February 2017)
  • 24 Feb 2017 Radius Health has patents pending for abaloparatide for microneedle application in USA, Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, and Ukraine (Radius Health's form 10-K, filed in February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top